Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding a Phase II trial for a lung cancer treatment and the addition of a new revision number. The collaborators' information has been streamlined.SummaryDifference5%
- Check20 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 20, 2025.SummaryDifference0.1%
- Check27 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous date of February 20, 2025, and version 2.14.2.SummaryDifference0.1%
- Check63 days agoChange DetectedThe webpage has updated its last update dates to February 2025, reflecting the most current information available.SummaryDifference0.6%
- Check78 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.4%
- Check85 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.